COLUMBUS, Ohio – Tiny vesicles released by tumors cells are taken up by healthy immune cells, causing the immune cells to discharge chemicals that foster cancer-cell growth and spread, according to a study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and at Children's Hospital in Los Angeles.
The study uses lung cancer cells to show that the vesicles contain potent regulatory molecules called microRNA, and that the uptake of these molecules by immune cells alters their behavior. The process in humans involves a fundamental receptor of the immune system called Toll-like receptor 8 (TLR8).
The findings, published in the early edition of the Proceedings of the National Academy of Sciences, suggest a new strategy for treating cancer and diseases of the immune system, the researchers say, and a new role for microRNA in the body.
"This study reveals a new function of microRNA, which we show binds to a protein receptor," says principal investigator Dr. Carlo Croce, director of Ohio State's Human Cancer Genetics program and a member of the OSUCCC – James Molecular Biology and Cancer Genetics program. "This tells us that some cancer-released microRNAs can bind and activate a receptor in a hormone-like fashion, and this has not been seen before."
MicroRNAs help control the type and amount of proteins that cells make, and they typically do this by binding with the messenger-RNA that encodes a protein.
"In this study we discovered a completely new mechanism used by cancer to grow and spread, therefore we can develop new drugs that fight tumors by entering this newly identified breach in cancer's fortress," says co-corresponding author and first author Dr. Muller Fabbri, assistant professor of Pediatrics and Molecular Biology and Immunology at the Keck School of Medicine of the University of Southern California.
"Equally exciting, we show that this mechanism involves a fundamental receptor of the immune system, TLR8, suggesting that the implications of this discovery may extend to other diseases such as autoimmune and inflammatory diseases," Fabbri says.
Key findings of the study include the following:
Funding from the NIH/National Cancer Institute (grants CA150297, CA135030, CA124541, and CA148302) and a 2009 Kimmel Foundation Fellowship supported this research.
Other researchers involved in this study were Alessio Paone, Federica Calore, Roberta Galli, Eugenio Gaudio, Ramasamy Santhanam, Francesca Lovat, Paolo Fadda, Charlene Mao, Nicola Zanesi, Melissa Crawford, Gulcin H. Ozer, Dorothee Wernicke, Hansjuerg Alder, Michael A. Caligiuri, Patrick Nana-Sinkam and Danilo Perrotti of Ohio State University; and Gerard J. Nuovo of Phylogeny, Inc.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S.News & World Report.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.